IAMA Therapeutics

IAMA Therapeutics is committed to developing innovative drugs for the treatment of brain diseases with unmet medical needs. IAMA Therapeutics pushes the boundaries of neuroscience drug discovery, developing new medicines and transforming the lives of individuals suffering from brain disorders. We aim to integrate emerging advances in drug discovery and neurobiology to build a leading next-generation neuroscience pipeline. IAMA Therapeutics has developed a platform to identify and advance diverse classes of small molecules for the selective inhibition of the sodium-potassium-chloride cotransporter (NKCC1) and other therapeutic targets associated with central nervous system disorders characterized by neuronal imbalance, including primary and secondary autism, epilepsy, and movement disorders.